1. Product and Company Identification

PRODUCT NAME: AUBAGIO® Tablets
7 mg, 14 mg

Substance name: Teriflunomide

Supplier:
Sanofi-aventis U.S. LLC
A SANOFI COMPANY
55 Corporate Drive
Bridgewater, NJ 08807

24-Hour Transport Emergency, US (Chemtrec):	**(800) 424-9300**
24-Hour Transport Emergency, outside US (Chemtrec):	**(703) 527-3887**
US Customer Service	**(800) 207-8049**
24-Hour Emergency, sanofi-aventis US:	**(908) 981-5550**

Product use: **Pharmaceutical product.**

2. Hazards Identification

2.1 Classification in accordance with 29 CFR 1910.1200

Classification of the finished drug product is not required according to OSHA 29 CFR 1910.1200. The following information is provided for the drug substance, teriflunomide:

Classification:
Acute toxicity, Category 3
Reproductive toxicity, Category 1B

2.2 Label elements in accordance with 29 CFR 1910.1200

Labeling of the finished drug product is not required according to OSHA 29 CFR 1910.1200. The following information is provided for the drug substance, teriflunomide:

Signal Word: Danger

Hazard Statement(s): Toxic if swallowed. May damage the unborn child.

Symbol(s): Skull and crossbones; Health Hazard.

Precautionary Statement(s):

- Prevention: Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Wear protective gloves. Wash hands thoroughly after handling. Do not eat, drink or smoke when using this product.

- Response: If swallowed: Immediately call a poison center. Rinse mouth. If exposed or concerned: Get medical advice.

- Storage: Store locked up.

- Disposal: Dispose of in accordance with applicable regional, national and local laws and regulations.

2.3 Hazards Not Otherwise Classified (HNOC)

Not classified.

---

3. Composition/Information on Ingredients

Chemical Name:	**Common Name:**	**CAS #:**	**Percentage or concentration range**
(Z)-2-Cyano-3-hydroxy-but-2-enoic acid-(4-trifluoromethylphenyl)-amide	Teriflunomide	163451-81-8	7 or 14 mg per tablet

Inactive Ingredients: Lactose monohydrate, corn starch, hydroxypropylcellulose, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate.
The film coating for the 14 mg tablet is made of hypromellose, titanium dioxide, talc, polyethylene glycol and indigo carmine aluminum lake.
In addition to these, the 7 mg tablet film coating includes iron oxide yellow.

---

4. First Aid Measures

4.1 First aid procedures

Eye contact: In case of contact with dust from broken tablets, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lenses if worn. Get medical attention.

Skin contact: In case of contact with broken tablets, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if irritation develops and persists.

Ingestion: If swallowed, call a poison center or physician immediately. Do NOT induce vomiting unless directed to do so by a physician. Never give anything by mouth to an unconscious person. Rinse mouth thoroughly with water.

Inhalation: If dust from broken tablets is inhaled, remove to fresh air. If breathing is difficult, trained personnel should give oxygen. Get medical attention.

4.2 Most important symptoms and effects, both acute and delayed

Fetal harm. Hepatotoxicity. Elevated liver enzymes (ALT and AST), alopecia and rash.

4.3 Indication of any immediate medical attention and special treatment needed

Treat symptomatically and supportively.

---

5. Fire Fighting Measures

5.1 Extinguishing media

Suitable extinguishing media: All means: water, carbon dioxide, foam or dry chemical.

Unsuitable extinguishing media: Strong water jet.

5.2 Specific hazards arising from the chemical

Hazardous combustion products: Carbon monoxide, carbon dioxide, oxides of nitrogen.

5.3 Special Protective Equipment and Precautions for Fire-fighters

In case of fire, use full firefighting turnout (bunker) gear and self-contained breathing apparatus (SCBA). Keep personnel upwind and away from fire. Move container from fire area if you can do it without risk. Do not scatter spilled material with high-pressure water streams. Dike fire-control water for later disposal.

6. Accidental Release Measures

6.1 Personal precautions and Protective Equipment:

Eye protection, respiratory protective equipment, and suitable protective clothing should be worn if significant dust emissions are generated from broken or crushed tablets.

6.2 Emergency Procedures:

Follow local workplace procedures. Prevent the product from entering the environment. Avoid discharges to sewers, drains, waterways, or onto the ground.

6.3 Methods for containment:

Vacuum or scoop up, moisten any dust with water before collection with a shovel or broom.

6.4 Methods for clean-up:

Place material in suitable container for disposal. Wash the floor with plenty of water, absorb or retain the cleaning water for disposal.

7. Handling and Storage

7.1 Precautions for Safe Handling

Use with adequate ventilation. Avoid breathing dust if tablets are crushed or spilled. Do not get dust in eyes or on skin. Wash thoroughly after handling.

7.2 Conditions for Safe Storage

Store at 68°F to 77°F (20°C to 25°C) with excursions permitted between 59°F and 86°F (15°C and 30°C).

8. Exposure Controls/Personal Protection

8.1 Exposure Limits

Sanofi-aventis occupational exposure band: 1 - 10 micrograms/m^3, 8-hour TWA.

8.2 Appropriate Engineering Controls

Provide adequate ventilation. No other specific controls are needed under normal handling conditions.

8.3 Individual Protection Measures

Eye/face protection: Safety glasses or safety goggles should be worn if there is a potential for dust exposure from broken or crushed tablets.

Skin protection: Suitable protective gloves should be worn, especially if handling the unfinished product or broken or crushed tablets.

Respiratory protection: None normally required. Approved respiratory protection should be worn if there is a potential for exposure to dust from handling operations or from broken or crushed tablets.

General hygiene considerations: Suitable work clothes. Wash hands before breaks and at the end of the work shift.

9. Physical and Chemical Properties

Appearance: Blue or greenish-blue film-coated tablets.
Odor: None.
Odor threshold: Not applicable.
pH: Not determined.
Melting point (teriflunomide): 229 - 230 °C.
Initial boiling point/boiling point range: Not applicable.
Flash point: Not applicable.
Evaporation rate: Not applicable.
Flammability: Not applicable.
Upper/lower flammability or explosive limits: Not applicable.
Vapor pressure: Not applicable.
Vapor density: Not applicable.
Relative density: Not applicable.
Solubility, water (teriflunomide): 21 mg/L.

Partition coefficient: n-octanol/water: Log Kow = 2.25. Method: Calculation (Hansch/Leo).
Auto-ignition temperature: Not determined.
Decomposition temperature: Not determined.
Viscosity: Not determined.

---

10. Stability and Reactivity

10.1 Reactivity

Not a reactive material under normal handling conditions.

10.2 Chemical Stability

Stable under normal handling conditions.

10.3 Possibility of hazardous reactions

None known.

10.4 Conditions to Avoid

Keep away from heat, sparks and flames.

10.5 Incompatible materials

Strong oxidizing and reducing agents.

10.6 Hazardous decomposition products

Carbon monoxide, carbon dioxide, oxides of nitrogen.

---

11. Toxicological Information

The following information is for the active ingredient teriflunomide unless otherwise noted:

Information on likely routes of exposure: Exposure not expected under normal use. Dust from broken or crushed tablets could result in exposure to eyes, skin and respiratory tract.

Symptoms related to the physical, chemical and toxicological characteristics: Elevated liver enzymes (ALT and AST), alopecia and rash.

Effects of short-term (acute) exposure: Elevated liver enzymes (ALT and AST), alopecia and rash.

Effects of long-term (chronic) exposure: Hepatotoxicity. May cause fetal harm.

Acute toxicity (LD50):
Oral route, rat: 400 – 1,000 mg/kg.
Oral route, mouse: 100 - 200 mg/kg.

Skin corrosion/irritation: Non-irritant. Method: OECD 404.

Serious eye damage/irritation: Non-irritant based on in vitro tests.

Sensitization: Non-sensitizing.

Specific target organ toxicity – single exposure (STOT-SE): No data.

Specific target organ toxicity – repeated exposure (STOT-RE): Liver.

Carcinogenicity: No evidence of carcinogenicity was observed in lifetime carcinogenicity bioassays in mouse and rat.

Not listed by NTP, not found to be a potential carcinogen by IARC or OSHA.

Titanium dioxide has been classified by IARC as 2B: Possibly carcinogenic to humans. Tumors were observed at high dose in animal studies by inhalation and intratracheal administration. Tumors were not observed by other routes.

Reproductive toxicity and teratogenicity: When teriflunomide was administered to pregnant rats throughout the period of organogenesis, high incidences of fetal malformation and embryofetal death were observed at doses not associated with maternal toxicity.

Administration of teriflunomide to pregnant rabbits throughout organogenesis resulted in high incidences of fetal malformation and embryofetal death at doses associated with minimal maternal toxicity.

In studies in which teriflunomide was administered to rats during gestation and lactation, decreased growth, eye and skin abnormalities, and high incidences of malformation (limb defects) and postnatal death were observed in the offspring at doses not associated with maternal toxicity.

Mutagenicity: Teriflunomide was negative in the in vitro bacterial reverse mutation (Ames) assay, the in vitro HPRT assay, and in in vivo micronucleus and chromosomal aberration assays. Teriflunomide was positive in an in vitro chromosomal aberration assay in human lymphocytes, with and without metabolic activation.

Aspiration hazard: Not applicable.

12. Ecological Information

The following information is for the active ingredient teriflunomide unless otherwise noted:

12.1. Ecotoxicity

GHS Chronic aquatic toxicity, Category 3. Harmful to aquatic life with long lasting effects.

Fish toxicity (LC50): 50 - 100 mg/l
Species: zebra fish
Exposure duration: 96 h
Method: OECD 203

Toxicity on invertebrates (EC50): > 100 mg/l
Species: Daphnia magna
Exposure duration: 48 h

12.2. Persistence and degradability

Biological degradability: approx. 1 %
Not readily biodegradable.
Testing period: 28 day
Method of analysis: Theoretical oxygen demand
Method: OECD 301 E

12.3. Bioaccumulative potential

Unlikely to be bioaccumulable in living organisms (Log Pow < 4).

12.4 Mobility in soil

Not determined.

12.5 Other adverse effects

Not determined.

13. Disposal Considerations

13.1 Disposal of product waste

Disposal should be in accordance with applicable regional, national and local laws and regulations. Local regulations may be more stringent than regional or national requirements.

13.2 Disposal of packaging waste

Dispose of in a safe manner in accordance with federal, state and local environmental regulations. Empty packages, containers or liners may contain product residue.

14. Transport Information

14.1 Basic shipping information, finished product

U.S. DOT	Not a regulated material.
ICAO/IATA	Not a regulated material.
IMDG	Not a regulated material.

15. Regulatory Information

US Regulations
CERCLA Hazardous Substance List (40 CFR 302.4): Not listed.
Clean Water Act Section 311 Hazardous Substances (40 CFR 117.3): Not listed.
Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130): Not listed.
SARA Title III:
Section 302 Extremely Hazardous Substance (40 CFR 355, Appendix A): Not listed.
Section 313 Toxic Release Inventory (40 CFR 372): Not listed.

State Regulations
California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65): Not listed.
Massachusetts Right-To-Know List: Not listed.
New Jersey Right-To-Know List: Not listed.
Pennsylvania Right-To-Know List: Not listed.

16. Other Information

Teriflunomide is included in in the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016.

Other Information: The information contained herein is based upon data considered true and accurate. Sanofi-Aventis U.S. LLC makes no warranties, express or implied, as to the adequacy of the information contained herein. This information is offered solely for the user's consideration, investigation and verification. Report to the manufacturer any allegations of health effects resulting from handling or accidental contact with this material.

Abbreviations and Acronyms
CAS: Chemical Abstracts Service
DOT: U.S. Department of Transportation
EST: Eastern standard time (U.S.)
IATA: International Air Transport Association
IMDG: International Maritime Dangerous Goods Code
LC50: Lethal concentration, 50%
LD50: Lethal dose, 50%
OEL: Occupational Exposure Limit
PPE: Personal Protection Equipment
SDS: Safety Data Sheet
STEL: Short-term exposure limit
TWA: Time-weighted average
U.S.: United States

Date Prepared: November 16, 2016

Second version.